期刊文献+

^125碘粒子组织间放疗时医护人员受照水平的研究 被引量:2

原文传递
导出
摘要 目的探讨^125碘(^125I)粒子植入治疗过程中医护人员的受照水平。方法利用手提式辐射探测仪监测21例恶性肿瘤患者植入^125I粒子整个过程中医护人员有关部位的受照剂量率,计算相应部位的年受照剂量当量;同时通过热释光个人剂量仪(TLD)监测操作人员的累积剂量。结果(1)实时剂量监测:医护人员手掌、胸部和眼睛等部位在无防护状态下最高年剂量当量分别为(232.84±12.01)、(13.42±1.25)、(26.21±1.72)mSv/a;有屏蔽防护时最高年剂量当量分别为(32.92±2.65)、(0.47±0.06)、(0.94±0.09)mSv/a。(2)累积剂量监测:技术员和医生胸部年剂量当量分别为(0.380±0.05)、(0.500±0.05)mSv/a,该监测结果与实时剂量监测结果的差异无统计学意义(P〉0.05)。结论^125I粒子组织间放疗过程中医护人员相关部位的受照水平明显低于国家标准,从外照射防护的角度讲近期是安全的、可接受的。
出处 《中华劳动卫生职业病杂志》 CAS CSCD 北大核心 2008年第12期747-748,共2页 Chinese Journal of Industrial Hygiene and Occupational Diseases
  • 相关文献

参考文献3

二级参考文献17

  • 1陆普选,贺国辉,林德义,罗晓东,周绪堂,吴九发,曾来铎.介入治疗或合并手术、放射治疗中晚期肺癌的疗效观察(附189例报告)[J].现代诊断与治疗,1994,5(2):83-85. 被引量:9
  • 2高耀明,许昌韶,王建平,杨吉成,金苏华.低剂量IL—2和低剂量放/化疗综合治疗晚期癌症的初步研究[J].苏州医学院学报,1995,15(4):656-657. 被引量:2
  • 3Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys,2000,47:1261-1266.
  • 4Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys,1997,39:347-353.
  • 5Molloy JA, Williams MB. Treatment planning considerations and quality assurance for CT-guided transischiorectal implantation of the prostate. Med Phys,1999,26:1943-1951.
  • 6Martinez-Monge R, Nag S, Nieroda CA, et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer,1999,85:1218-1225.
  • 7Vikram B, Mishra S.Permanent iodine-125 implants in postoperative radiotherapy for head and neck cancer with positive surgical margins. Head Neck,1994,16:155-157.
  • 8Kumar PP, Patil AA, Leibrock LG,et al. Continuous low dose rate brachytherapy with high activity iodine-125 seeds in the management of meningiomas. Int J Radiat Oncol Biol Phys,1993,25:325-328.
  • 9Lee DJ, Liberman FZ, Park RI, et al. Intraoperative I-125 seed implantation for extensive recurrent head and neck carcinomas. Radiology,1991,178:879-882.
  • 10Heelan RT, Hilaris BS, Anderson LL, et al. Lung tumors: percutaneous implantation of I-125 sources with CT treatment planning. Radiology, 1987,164:735-740.

共引文献189

同被引文献19

  • 1郭金和,滕皋军,朱光宇,何仕诚,李国昭,刘振生,丁惠娟.^(125)I放射粒子在肿瘤介入治疗中的应用[J].介入放射学杂志,2005,14(6):613-617. 被引量:27
  • 2王晓峰,白玫,孙雪梅,翟风杰,彭明辰.CA与PTCA中医务人员的剂量学研究[J].中国辐射卫生,2006,15(1):13-16. 被引量:9
  • 3Kaulich TW, Bamberg M. Radiation protection of persons living close to patients with radioactive implants[J]. Strahlenther Onkol, 2010, 186(2):107-112.
  • 4Anglesio S, Calamia E, Fiandra C, et al. Prostate brachytherapy with iodine-125 seeds: radiation protection issues[J]. Tumori, 2005, 91 (4):335-338.
  • 5Dauer LT, Kollmeier MA, Williamson MJ, et al. Less-restrictive, patient-specific radiation safety precautions can be safely pre- scribed after permanent seed implantation[J]. Brachytherapy, 2010, 9(2):101-111.
  • 6Miller D, Van E, Bartal G. Occupational radiation protection for in- terventional radiology society of Europe and the society of interven- tional radiology[J].CIRSE, 2010, 32(2):230-239.
  • 7Lie OO, Paulsen GU, Wohni T. Assessment of effective dose and dose to the lens of the eye for the interventional cardiologist[J].Ra- diat Prot Dosim, 2008, 132(3):313-318.
  • 8NCRP. Use of personal monitors to estimate effective dose equiva- lent and effective dose to workers for external exposure to low-let radiation[M]. Report No.122. Bethesda: NCRP, 1995:64.
  • 9ICRP. Statement on tissue reactions. ICRP ref 4825-3093-1464. http://www.icrp.org/docs/ ICRP Statement on tissue reactions. pdf. 2011-04-21.
  • 10Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis [ J ]. Cancer Epidemiol, 2014, 38: 435-441.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部